Will I lose my hair if I stop using RU58841? (Spoiler: I might.)

RU58841 is an experimental topical anti-androgen that hair-loss communities discuss as a possible option for androgenic alopecia — commonly known as male or female pattern baldness. In laboratory and animal studies it acts as a non-steroidal anti-androgen (NSAA), blocking dihydrotestosterone (DHT) from binding to receptors in the hair follicle. DHT is a byproduct of testosterone and is largely responsible for shrinking hair follicles in people genetically predisposed to hair loss. RU58841 is not approved as a medicine in any country, no large or long-term human trial has been published, and its long-term safety is unknown.

So what do the available sources say happens if you stop using it? Here is what the research and the community reports actually show.

What Happens When You Stop RU58841?

No published study has followed people who started and then stopped RU58841, so this section draws on how topical anti-androgens behave in animal studies and on what community members describe.

RU58841 is not described in the literature as a cure for hair loss; in the animal work it suppresses androgen signalling only while it is being applied. Once application stops, DHT is again free to bind to the receptors, and the miniaturization process would be expected to resume. That means any regrowth or preservation attributed to RU58841 could gradually reverse.

Community members who stop commonly report shedding within a few weeks to a few months, though the timeline they describe varies widely from person to person. The hair growth cycle has three phases: anagen (growth), catagen (transition), and telogen (resting and shedding). Anti-androgens are understood to work by keeping follicles in the anagen phase for longer; when androgen blockade is removed, hairs would be expected to move into telogen and shed. This mechanism is inferred from androgen biology rather than measured in a human RU58841 trial.

Users also describe what they call "catch-up hair loss" — the idea that after stopping, loss accelerates until it reaches the point it would have reached had treatment never started. This is a community concept borrowed from discussion of finasteride and minoxidil; there is no published human data on catch-up loss after RU58841 specifically.

A related idea circulating in the same threads is that follicles kept alive by treatment collapse faster than healthier ones once it is withdrawn. This has not been tested for RU58841 and should be read as a hypothesis, not a finding. Users who experience it describe it as demoralising, especially after seeing regrowth.

Dermatology sources also note that any abrupt change in a scalp routine can trigger telogen effluvium — a shedding pattern in which more hairs than usual enter the telogen phase early. That kind of shedding is usually temporary, but where androgenic alopecia is also present, the regrowth may not return to its prior fullness.

Understanding the Mechanism of RU58841

RU58841 is a non-steroidal anti-androgen (NSAA). In the published animal and cell studies it competes with dihydrotestosterone (DHT) for the androgen receptor. DHT is a byproduct of testosterone that, in people with a genetic predisposition to hair loss, is associated with hair follicles shrinking over time. Smaller follicles eventually stop producing visible hair, leading to thinning and baldness.

Unlike finasteride, which lowers DHT levels throughout the body, RU58841 was designed as a locally acting compound intended to work at the site of application. Battmann and colleagues (1994) reported strong local anti-androgen activity in animal models, and Pan and colleagues (1998) reported hair regrowth in the bald scalp of stumptailed macaques. De Brouwer and colleagues (1997) reported an effect on human balding scalp grafts maintained on testosterone-conditioned nude mice. All of this work is preclinical.

The "local only" design should not be read as a guarantee of no systemic effect in people. Rat pharmacokinetic work by Cousty-Berlin and colleagues (1994) found that this class of non-steroidal anti-androgens is absorbed and metabolised to a shared metabolite that carries systemic activity. No human pharmacokinetic data for RU58841 have been published, and some community members report effects they believe were systemic. Systemic absorption in humans is unmeasured, not ruled out.

Whatever blocking effect there is would also not be permanent. Once application stops, receptor blockade would end and DHT would again reach the follicle. In the community's framing, RU58841 buys time rather than resetting or curing the process — and that framing, too, rests on mechanism and anecdote rather than on a human trial.

Why Does Shedding Happen When You Stop?

Community reports and androgen biology point to two processes:

1. DHT Reattachment: DHT returns to the receptors, and the miniaturization process would be expected to resume. Follicles that had been preserved or partially regrown start shrinking again, leading to shedding and thinning.

2. Telogen Effluvium: A temporary shedding phase that can follow a sudden change in a hair routine. Stopping any hair-loss treatment — not just RU58841 — can push follicles into premature shedding. Users describe it as similar to the shedding reported when starting or stopping minoxidil.

Can You Minimize the Fallout?

There is no evidence that anything reliably prevents shedding after stopping RU58841. Some users report a smoother transition when they taper the frequency of application rather than stopping abruptly; the reasoning they give is that it gives follicles time to adjust to the return of DHT. This has not been studied.

Community members also discuss moving onto approved treatments such as minoxidil or finasteride during the transition. Minoxidil is understood to extend the growth phase, and finasteride lowers DHT systemically — different mechanisms, each with its own risks and its own side-effect profile. Finasteride is a prescription drug in most countries; ask your prescriber whether it is appropriate for you rather than starting it on the strength of forum advice. One of the biggest limitations here is the absence of large-scale, long-term human trials of RU58841 at all: most data comes from animal research or anecdotal reports from online communities, which makes any prediction about safety or long-term use unreliable.

Final Thoughts: Is RU58841 a Shortcut to Regrowth — or a Time Bomb Waiting to Go Off?

RU58841 is presented in the community as a promise of restored hair and halted thinning, but the picture in the sources is more complicated. It is an experimental, unapproved compound: the efficacy evidence is preclinical, the human evidence is anecdotal, and the long-term safety in people is unknown. Community members who stop commonly report rapid shedding, and some describe it as worse than their pre-treatment state, though that comparison is self-reported and unmeasured.

If you are drawn to RU58841 as a quick fix, the questions the sources raise are: what would you do if you had to stop, and what are you accepting on safety that nobody has measured?

What the available material does not support is treating it as a cure. Users who report the best experience describe it as a long commitment; those who stop describe losing what they gained.

RU58841 remains an experimental, unapproved compound — it is sold as a research chemical, not as a medicine, in the United States and elsewhere. The material available suggests stopping it may be followed by significant shedding and a return to your underlying rate of hair loss.

Talk to a doctor or pharmacist before starting, stopping or combining RU58841 or any hair-loss treatment. Because RU58841 is unregulated, what is in a given vial — purity, concentration, contaminants — is not verified by anyone, and a clinician should know what you are using before you add or withdraw anything else.

User Experiences

Users debate whether RU58841 works as a standalone treatment or whether it is better combined with finasteride or dutasteride. Some raise concerns about side effects such as gynecomastia, which leads to mentions of other compounds like pyrilutamide and alfatradiol. Pyrilutamide is also an unapproved investigational compound and alfatradiol is only licensed in a few countries; neither is a validated substitute, and both would be worth raising with a clinician rather than swapping in from a thread.

Not everyone reports a smooth experience. One user described severe side effects, including heart palpitations and shortness of breath, which led them to quit RU58841 altogether; they reported preferring minoxidil and finasteride. These are individual accounts, not trial data. Overall, community discussion of RU58841 is divided: it has no clinical approval and users report side effects, and those who stop generally expect hair loss to resume unless another treatment is maintained.

References:

Battmann, T., Bonfils, A., Branche, C., et al. (1994). RU 58841, a new specific topical antiandrogen: a candidate of choice for the treatment of acne, androgenetic alopecia and hirsutism. Journal of Steroid Biochemistry and Molecular Biology, 48(1), 55-60. https://pubmed.ncbi.nlm.nih.gov/8136306/

Pan, H. J., Wilding, G., Uno, H., et al. (1998). Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 9(1), 39-43. https://pubmed.ncbi.nlm.nih.gov/9798729/

De Brouwer, B., Tetelin, C., Leroy, T., et al. (1997). A controlled study of the effects of RU58841, a non-steroidal antiandrogen, on human hair production by balding scalp grafts maintained on testosterone-conditioned nude mice. British Journal of Dermatology, 137(5), 699-702. https://pubmed.ncbi.nlm.nih.gov/9415227/

Cousty-Berlin, D., Bergaud, B., Bruyant, M. C., et al. (1994). Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: relation of their systemic activity to the formation of a common metabolite. Journal of Steroid Biochemistry and Molecular Biology, 51(1-2), 47-55. https://pubmed.ncbi.nlm.nih.gov/7947350/

Reddit user. (2025, January 14). Methods Of Staying Safe On Ru58841 - My 2 Cents. r/tressless. Retrieved from https://reddit.com/r/tressless/comments/1i0x5po/methods_of_staying_safe_on_ru58841_my_2_cents/

Reddit user. (2025, January 8). Any RU58841 users see better/faster regrowth after upping dosage?. r/tressless. Retrieved from https://reddit.com/r/tressless/comments/1hwseqw/any_ru58841_users_see_betterfaster_regrowth_after/

Reddit user. (2024, December 28). Anyone who used RU58841 without fin/dut?. r/tressless. Retrieved from https://reddit.com/r/tressless/comments/1hntviz/anyone_who_used_ru58841_without_findut/

Reddit user. (2024, December 23). A scary individual report of RU58841. r/tressless. Retrieved from https://reddit.com/r/tressless/comments/1hkieio/a_scary_individual_report_of_ru58841/